This protocol is designed to better characterize a sub-population of peanut sensitized
individuals who may be non-allergic, despite significant sensitization, or who may be
allergic, but at high threshold doses. By specifically targeting participants who met the
initial screening criteria of the active adult PN OIT study, Protocol 2012p002153 / AADCRC
MGH-004 (MGH-004), but failed to react during the pre-treatment 443 mg challenge to peanut,
the investigators anticipate that the investigators will identify individuals who have become
spontaneously tolerant, despite persistent sensitization. The investigators might also find
that clinical sensitivity persists but only with higher thresholds, or that sensitivity has
increased (or is variable) since the previous allergen exposure. By repeating DBPCFCs through
to a full serving dose (7.4 gram), the investigators will distinguish participants who react
only at higher doses from those who were not truly peanut allergic, address whether their
sensitivity has changed, and have the opportunity to further investigate their immune
response to peanut allergen.
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)